Coadministration of ribavirin and arenaviral entry inhibitor LHF-535 enhances antiviral benefit against authentic lassa virus
Authors:
Open Access
- 1 June 2025
- journal article
- Published by KEAI Publishing in Virologica Sinica
- Vol. 40 (3) , 491-494
Abstract
• A new strain of Lassa virus (LASV) was successfully isolated and characterized. • The combination of ribavirin and LHF-535 has been demonstrated to exhibit synergistic effects in inhibiting LASV. • The findings provide new directions for the development of antiviral drugs and vaccines for Lassa fever.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC2605504, 2022YFC2303300)
- Chinese Academy of Sciences
- National Natural Science Foundation of China (82172273, 31670165)
- State Key Laboratory of Virology (2023JZZD-01)
This publication has 16 references indexed in Scilit:
- Hexestrol, an estrogen receptor agonist, inhibits Lassa virus entryJournal of Virology, 2024
- Coadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and diseaseAntiviral Research, 2024
- A novel BSL-2 Lassa virus reverse genetics system modelling the complete viral life cycleEmerging Microbes & Infections, 2024
- Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2022
- Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, NigeriaClinical Infectious Diseases, 2022
- Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysisInternational Journal of Infectious Diseases, 2019
- Structure-activity relationship optimization for lassa virus fusion inhibitors targeting the transmembrane domain of GP2Protein & Cell, 2019
- Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa FeverClinical Infectious Diseases, 2017
- Identification of a Broad-Spectrum Arenavirus Entry InhibitorJournal of Virology, 2008
- Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature, 2005